Intercell

Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012.[2] Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.[3] It employs 400 people in Austria, Scotland and the United States.

Intercell AG

Type	Aktiengesellschaft
Traded as	WBAG: ICLL OTCQX: INRLY
Industry	Biotechnology
Fate	Merged with Vivalis SA
Successor	Valneva SE
Founded	1998
Defunct	2013 (2013)
Headquarters	Vienna , Austria
Key people	Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board)
Products	Development of vaccines
Revenue	€34.2 million (2010)[1]
Operating income	(€251.2 million) (2010)[1]
Net income	(€255.2 million) (2010)[1]
Total assets	€225.2 million (end 2010)[1]
Total equity	€121.1 million (end 2010)[1]
Number of employees	410 (average, 2010)[1]
Website	www.intercell.com

It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology.[4][5]

Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production.

The most important projects of Intercell are:

• Vaccine against Japanese encephalitis (approved in Europe, America and Australia)[6][7][8]

• Therapeutic vaccine against hepatitis C (in clinical phase II)[9]
• Antigen identification program and adjuvant technologies.
• Vaccine Enhancement Patch to improve prevention against pandemic influenza (in collaboration with U.S. Department of Health and Human Services, in clinical phase II)